Lummis Asset Management LP Buys 861 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Lummis Asset Management LP lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,891 shares of the medical research company’s stock after purchasing an additional 861 shares during the quarter. Thermo Fisher Scientific comprises about 2.8% of Lummis Asset Management LP’s investment portfolio, making the stock its 9th largest position. Lummis Asset Management LP’s holdings in Thermo Fisher Scientific were worth $2,407,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Metis Global Partners LLC grew its stake in Thermo Fisher Scientific by 2.7% in the 3rd quarter. Metis Global Partners LLC now owns 21,306 shares of the medical research company’s stock valued at $13,179,000 after acquiring an additional 565 shares during the last quarter. Curi RMB Capital LLC grew its stake in Thermo Fisher Scientific by 6.1% in the 3rd quarter. Curi RMB Capital LLC now owns 17,483 shares of the medical research company’s stock valued at $10,814,000 after acquiring an additional 1,000 shares during the last quarter. Wealthstream Advisors Inc. acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $207,000. Zions Bancorporation N.A. lifted its holdings in Thermo Fisher Scientific by 8.6% in the 3rd quarter. Zions Bancorporation N.A. now owns 11,455 shares of the medical research company’s stock valued at $7,086,000 after purchasing an additional 907 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Thermo Fisher Scientific by 52.2% during the 3rd quarter. KBC Group NV now owns 376,193 shares of the medical research company’s stock worth $232,702,000 after purchasing an additional 128,968 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,150 shares of company stock valued at $20,651,865. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TMO shares. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Bank of America boosted their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Finally, Bernstein Bank boosted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Stock Down 0.7 %

Shares of Thermo Fisher Scientific stock traded down $3.91 during trading on Thursday, reaching $537.99. The company had a trading volume of 115,474 shares, compared to its average volume of 1,455,533. The company has a market cap of $205.78 billion, a price-to-earnings ratio of 33.97, a price-to-earnings-growth ratio of 3.57 and a beta of 0.79. Thermo Fisher Scientific Inc. has a fifty-two week low of $463.99 and a fifty-two week high of $627.88. The firm’s fifty day moving average is $589.87 and its 200-day moving average is $583.04. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm earned $5.69 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.